respiratory

ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections

May 11, 2026 04:00 ET  | Source: ENA Respiratory MELBOURNE, Australia, May 11, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a…

2 weeks ago

ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection

SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II…

7 months ago

Drger Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Respiratory Devices Innovation

Dräger recognized for pioneering innovations in respiratory care, delivering measurable improvements in patient outcomes, clinical efficiency, cost-effectiveness and critical care…

11 months ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…

11 months ago